Laquinimod in multiple sclerosis

Clinical Immunology

Volumn 142, Issue 1, 2012, Pages 38-43

  Giacomini, Paul S ^a,b   Bar Or, Amit ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Gadolinium enhancing T1 lesion; Immune modulator; ; Laquinimod; ; MRI; ; Multiple sclerosis;

Indexed keywords

LAQUINIMOD;

ARTHRALGIA; AXONAL INJURY; BRAIN CONTUSION; BREAST CANCER; BUDD CHIARI SYNDROME; BURNING SENSATION; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; DEMYELINATION; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; INFECTION; IRITIS; LIVER FUNCTION TEST; LIVER INJURY; MULTIPLE SCLEROSIS; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SIDE EFFECT; TONSILLITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUINOLONES;

EID: 84856214549     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.02.021     Document Type: Review

References (17)

1. Polman C., Barkhof F., Sandberg-Wollheim M., Linde A., Nordle O., Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005, 64:987-991.
2. Noseworthy J.H., Wolinsky J.S., Lublin F.D., Whitaker J.N., Linde A., Gjorstrup P., Sullivan H.C. Linomide in relapsing and secondary progressive MS: Part I: trial design and clinical results. North American Linomide Investigators. Neurology 2000, 54:1726-1733.
3. Tan I.L., Lycklama a Nijeholt G.J., Polman C.H., Ader H.J., Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler 2000, 6:99-104.
4. Wolinsky J.S., Narayana P.A., Noseworthy J.H., Lublin F.D., Whitaker J.N., Linde A., Gjorstrup P., Sullivan H.C. Linomide in relapsing and secondary progressive MS: Part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 2000, 54:1734-1741.
5. Jonsson S., Andersson G., Fex T., Fristedt T., Hedlund G., Jansson K., Abramo L., Fritzson I., Pekarski O., Runstrom A., Sandin H., Thuvesson I., Bjork A. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J. Med. Chem. 2004, 47:2075-2088.
6. Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin. Investig. Drugs 2009, 18:985-989.
7. Comi G., Pulizzi A., Rovaris M., Abramsky O., Arbizu T., Boiko A., Gold R., Havrdova E., Komoly S., Selmaj K., Sharrack B., Filippi M. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092.
8. Comi G., Abramsky O., Arbizu T., Boyko A., Gold R., Havrdova E., Komoly S., Selmaj K., Sharrack B., Filippi M. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult. Scler. 2010, 16(11):1360-1366.
9. Deltenre P., Denninger M.H., Hillaire S., Guillin M.C., Casadevall N., Briere J., Erlinger S., Valla D.C. Factor V Leiden related Budd-Chiari syndrome. Gut 2001, 48:264-268.
10. http://www.clinicaltrials.gov/ct2/show/NCT00509145?term=laquinimod+and+multiple+sclerosis&rank=2.
11. http://www.clinicaltrials.gov/ct2/show/NCT00605215?term=laquinimod&cond=multiple+sclerosis&rank=6.
12. Brunmark C., Runstrom A., Ohlsson L., Sparre B., Brodin T., Astrom M., Hedlund G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 130:163-172.
13. Yang J.S., Xu L.Y., Xiao B.G., Hedlund G., Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 2004, 156:3-9.
14. Zou L.P., Abbas N., Volkmann I., Nennesmo I., Levi M., Wahren B., Winblad B., Hedlund G., Zhu J. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002, 42:731-739.
15. Wegner C., Stadelmann C., Pfortner R., Raymond E., Feigelson S., Alon R., Timan B., Hayardeny L., Bruck W. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 227:133-143.
16. Gurevich M., Gritzman T., Orbach R., Tuller T., Feldman A., Achiron A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J. Neuroimmunol. 2010, 221:87-94.
17. Wegner Laquinimod Effects in Model of Chemically Induced Demyelination. Abstract Presentation, Charcot Meeting 2010.